13F filer · CIK 1103804 ↗
Viking Global
You are looking at Q1 2022. See the latest, Q2 2026 →
Reported value
$24.74B
−29% on the quarter before
Positions
91
16 new · 32 sold out
Top 10
40.0%
of the value
Est. gain
−$3.18B
on stocks held all quarter
Est. return
−13.9%
on those stocks since Q4 2021
Positions as of Mar 31, 2022, from Viking Global's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q4 2021. Striped tiles are options.
Largest buys
Since Q4 2021, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Mastercard~$641.0MNew · 0.0% → 2.6%+1,793,488 shares
- Amazon~$471.6MAdded · 2.7% → 5.6%+144,654 shares
- International Flavors&Fragra~$431.6MAdded · 0.2% → 2.0%+3,286,245 shares
- Xp Inc~$284.2MNew · 0.0% → 1.1%+9,443,312 shares
- Otis Worldwide Corp~$272.3MNew · 0.0% → 1.1%+3,538,164 shares
- Fortive Corp~$216.2MAdded · 1.9% → 3.0%+3,548,215 shares
- Marsh & Mclennan Cos Inc~$168.6MAdded · 0.6% → 1.6%+989,073 shares
- Thermo Fisher Scientific Inc~$161.6MAdded · 0.4% → 1.2%+273,638 shares
- Shopify Inc~$151.2MNew · 0.0% → 0.6%+223,721 shares
- Hdfc Bank Ltd~$136.2MAdded · 0.9% → 1.8%+2,220,379 shares
Largest sells
Since Q4 2021, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Humana Inc~$1.24BSold out · 3.6% → 0.0%−2,663,368 shares
- Ginkgo Bioworks Holdings Inc~$1.16BCut · 8.1% → 0.8%−288,000,000 shares
- Twilio~$784.9MSold out · 2.3% → 0.0%−2,980,398 shares
- Coupa Software Inc~$658.8MSold out · 1.9% → 0.0%−4,168,030 shares
- General Electric Co~$478.8MCut · 4.9% → 4.7%−5,232,678 shares
- Figs Inc~$406.3MSold out · 1.2% → 0.0%−14,742,689 shares
- Zimmer Biomet Holdings Inc~$317.1MSold out · 0.9% → 0.0%−2,496,245 shares
- Visa Inc.~$304.7MCut · 2.5% → 2.3%−1,373,759 shares
- Boston Scientific Corp~$271.2MCut · 2.3% → 2.3%−6,122,359 shares
- Assurant Inc~$268.7MSold out · 0.8% → 0.0%−1,723,771 shares
Holdings
As of Mar 31, 2022. Changes are in shares against Dec 31, 2021, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| T-Mobile Us IncCOM · shares +2.1% · price +10.7% | 7.0% | $1.72B | +$162.6M | ||||||||
| AmazonCOM · shares +52% · price −2.2% | 5.6% | $1.38B | −$20.7M | ||||||||
| General Electric CoCOM NEW · shares −29% · price −3.1% | 4.7% | $1.17B | −$38.0M | ||||||||
| MicrosoftCOM · shares +13% · price −8.3% | 4.1% | $1.02B | −$82.1M | ||||||||
| Brookfield Asset Mgmt IncCL A LTD VT SH · shares −7.4% · price −6.3% | 3.7% | $922.4M | −$62.1M | ||||||||
| Parker-Hannifin CorpCOM · shares +3.5% · price −10.8% | 3.6% | $898.2M | −$105.0M | ||||||||
| Fortive CorpCOM · shares +42% · price −20.1% | 3.0% | $733.2M | −$130.3M | ||||||||
| Api Group CorpCOM STK · shares +0.4% · price −18.4% | 2.8% | $703.7M | −$158.0M | ||||||||
| Chubb LimitedCOM · shares −13% · price +10.7% | 2.8% | $684.7M | +$65.9M | ||||||||
| Comcast Corp NewCL A · shares −0.9% · price −7.0% | 2.7% | $659.2M | −$49.4M | ||||||||
| Centene Corp DelCOM · shares −9.4% · price +2.2% | 2.7% | $657.2M | +$14.0M | ||||||||
| MastercardCL A · shares New | 2.6% | $641.0M | — | ||||||||
| Visa Inc.COM CL A · shares −35% · price +2.3% | 2.3% | $576.1M | +$13.1M | ||||||||
| Boston Scientific CorpCOM · shares −32% · price +4.3% | 2.3% | $568.6M | +$23.2M | ||||||||
| WorkdayCL A · shares +29% · price −12.3% | 2.2% | $539.6M | −$59.1M | ||||||||
| Aon PlcSHS CL A · shares +5.5% · price +8.3% | 2.1% | $518.8M | +$37.9M | ||||||||
| International Flavors&FragraCOM · shares +643% · price −12.8% | 2.0% | $498.7M | −$9.9M | ||||||||
| Roivant Sciences LtdSHS · shares 0% · price −51.0% | 1.8% | $435.9M | −$453.5M | ||||||||
| Hdfc Bank LtdSPONSORED ADS · shares +46% · price −5.7% | 1.8% | $433.8M | −$18.1M | ||||||||
| Royalty Pharma PlcSHS CLASS A · shares +4.4% · price −2.2% | 1.7% | $419.4M | −$9.2M | ||||||||
| Adaptive Biotechnologies CorCOM · shares 0% · price −50.5% | 1.7% | $416.3M | −$425.3M | ||||||||
| Guardant Health IncCOM · shares +15% · price −33.8% | 1.6% | $385.0M | −$171.4M | ||||||||
| Marsh & Mclennan Cos IncCOM · shares +78% · price −2.0% | 1.6% | $383.6M | −$4.3M | ||||||||
| UberCOM · shares −1.4% · price −14.9% | 1.5% | $372.4M | −$65.2M | ||||||||
| Match Group Inc NewCOM · shares +44% · price −17.8% | 1.2% | $298.4M | −$44.7M | ||||||||
| Total · 91 positions | 100% | $24.74B | −$3.18B |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q4 2021 to Q1 2022: 74 stocks held throughout, down $3.18B (−13.9%).
- T-Mobile Us Inc+$162.6M+11%
- Chubb Limited+$65.9M+11%
- Aon Plc+$37.9M+8%
- Procept Biorobotics Corp+$36.5M+40%
- Deere & Co+$29.3M+21%
- Guardant Health Inc−$171.4M−34%
- Bridgebio Pharma Inc−$173.8M−39%
- Ginkgo Bioworks Holdings Inc−$218.5M−52%
- Adaptive Biotechnologies Cor−$425.3M−51%
- Roivant Sciences Ltd−$453.5M−51%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 14, 2026 | $35.08B−2% | SEC ↗ |
| Q1 2026 | May 15, 2026 | $35.75B−5% | SEC ↗ |
| Q4 2025 | Feb 17, 2026 | $37.68B−2% | SEC ↗ |
| Q3 2025 | Nov 14, 2025 | $38.50B+11% | SEC ↗ |
| Q2 2025 | Aug 14, 2025 | $34.59B+10% | SEC ↗ |
| Q1 2025 | May 15, 2025 | $31.48B+2% | SEC ↗ |
| Q4 2024 | Feb 14, 2025 | $30.90B+13% | SEC ↗ |
| Q3 2024 | Nov 14, 2024 | $27.44B+5% | SEC ↗ |
| Q2 2024 | Aug 14, 2024 | $26.02B−3% | SEC ↗ |
| Q1 2024 | May 15, 2024 | $26.86B−2% | SEC ↗ |
| Q4 2023 | Feb 14, 2024 | $27.30B+11% | SEC ↗ |
| Q3 2023 | Nov 14, 2023 | $24.64B+1% | SEC ↗ |
| Q2 2023 | Aug 14, 2023 | $24.43B+15% | SEC ↗ |
| Q1 2023 | May 15, 2023 | $21.31B+7% | SEC ↗ |
| Q4 2022 | Feb 14, 2023 | $19.98B−8% | SEC ↗ |
| Q3 2022 | Nov 14, 2022 | $21.66B−1% | SEC ↗ |
| Q2 2022 | Aug 15, 2022 | $21.86B−12% | SEC ↗ |
| Q1 2022 | May 16, 2022 | $24.74B−29% | SEC ↗ |
| Q4 2021 | May 16, 2022 (amended) | $34.71B−5% | SEC ↗ |
| Q3 2021 | May 16, 2022 (amended) | $36.46B+11% | SEC ↗ |
| Q2 2021 | Aug 16, 2021 | $32.98B−2% | SEC ↗ |
| Q1 2021 | May 17, 2021 | $33.58B−8% | SEC ↗ |
| Q4 2020 | Feb 16, 2021 | $36.37B+31% | SEC ↗ |
| Q3 2020 | Nov 16, 2020 | $27.68B+20% | SEC ↗ |
| Q2 2020 | Aug 7, 2020 | $23.14B+20% | SEC ↗ |
| Q1 2020 | May 13, 2020 | $19.21B−10% | SEC ↗ |
| Q4 2019 | Feb 13, 2020 | $21.35B+11% | SEC ↗ |
| Q3 2019 | Nov 13, 2019 | $19.20B−14% | SEC ↗ |
| Q2 2019 | Aug 14, 2019 | $22.29B+28% | SEC ↗ |
| Q1 2019 | May 15, 2019 | $17.44B−1% | SEC ↗ |
| Q4 2018 | Feb 14, 2019 | $17.57B−3% | SEC ↗ |
| Q3 2018 | Nov 14, 2018 | $18.06B+3% | SEC ↗ |
| Q2 2018 | Aug 14, 2018 | $17.47B+5% | SEC ↗ |
| Q1 2018 | May 15, 2018 | $16.61B+2% | SEC ↗ |
| Q4 2017 | Feb 14, 2018 | $16.26B+5% | SEC ↗ |
| Q3 2017 | Nov 14, 2017 | $15.44B+4% | SEC ↗ |
| Q2 2017 | Aug 14, 2017 | $14.85B−34% | SEC ↗ |
| Q1 2017 | May 15, 2017 | $22.64B+3% | SEC ↗ |
| Q4 2016 | Feb 14, 2017 | $22.01B−5% | SEC ↗ |
| Q3 2016 | Nov 14, 2016 | $23.18B−2% | SEC ↗ |
| Q2 2016 | Aug 15, 2016 | $23.54B+4% | SEC ↗ |
| Q1 2016 | May 16, 2016 | $22.72B | SEC ↗ |